Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The trial proposed to evaluate the efficacy and safety of an inotuzumab ozogamicin followed
by an age-adapted intermediate intensive consolidation therapy and maintenance treatment in
patients with acute lymphoblastic leukemia older than 56 years